Lasa Supergenerics Ltd banner

Lasa Supergenerics Ltd
NSE:LASA

Watchlist Manager
Lasa Supergenerics Ltd Logo
Lasa Supergenerics Ltd
NSE:LASA
Watchlist
Price: 8.96 INR 0.34%
Market Cap: ₹448.9m

Relative Value

LASA doesn't have a meaningful market cap.

The Relative Value of one LASA stock under the Base Case scenario is hidden INR. Compared to the current market price of 8.96 INR, Lasa Supergenerics Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LASA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

LASA Competitors Multiples
Lasa Supergenerics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Lasa Supergenerics Ltd
NSE:LASA
448.9m INR 0.5 -1.2 -53.6 -4.1
US
Eli Lilly and Co
NYSE:LLY
964.4B USD 16.2 52.4 35.2 37.7
US
Johnson & Johnson
NYSE:JNJ
572.6B USD 6.1 21.4 14.9 18.2
CH
Roche Holding AG
SIX:ROG
284.4B CHF 4.6 30.2 12.8 14.9
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.2 11.9
UK
AstraZeneca PLC
LSE:AZN
217.3B GBP 5.2 31.9 15.2 22.3
CH
Novartis AG
SIX:NOVN
227.3B CHF 5.2 20.3 12.8 16.5
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4 12.3 8.6 10
US
Pfizer Inc
NYSE:PFE
151.1B USD 2.4 19.4 7.3 9.7
US
Bristol-Myers Squibb Co
NYSE:BMY
120.9B USD 2.5 20 7.1 9.3
P/E Multiple
Earnings Growth PEG
IN
Lasa Supergenerics Ltd
NSE:LASA
Average P/E: 24.9
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.4
54%
1
US
Johnson & Johnson
NYSE:JNJ
21.4
6%
3.6
CH
Roche Holding AG
SIX:ROG
30.2
29%
1
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.9
38%
0.8
CH
Novartis AG
SIX:NOVN
20.3
17%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.3
2%
6.1
US
Pfizer Inc
NYSE:PFE
19.4
26%
0.7
US
Bristol-Myers Squibb Co
NYSE:BMY
20
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Lasa Supergenerics Ltd
NSE:LASA
Average EV/EBITDA: 45.7
Negative Multiple: -53.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.2
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.2
10%
1.5
CH
Novartis AG
SIX:NOVN
12.8
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.6
1%
8.6
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Lasa Supergenerics Ltd
NSE:LASA
Average EV/EBIT: 98.6
Negative Multiple: -4.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.7
37%
1
US
Johnson & Johnson
NYSE:JNJ
18.2
6%
3
CH
Roche Holding AG
SIX:ROG
14.9
6%
2.5
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
22.3
23%
1
CH
Novartis AG
SIX:NOVN
16.5
12%
1.4
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10
0%
N/A
US
Pfizer Inc
NYSE:PFE
9.7
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.3
10%
0.9